Moderate to Vigorous Intensity Locomotor Training After Stroke: A Systematic Review

and Meta-Analysis of Mean Effects and Individual Response Variability

Pierce Boyne PT, DPT, PhD, NCS;¹ Allison Miller PT, DPT, PhD, NCS;² Owen Kubalak BS;¹ Caroline Mink BS;¹ Darcy S. Reisman PT, PhD;² George Fulk PT, PhD³

¹Department of Rehabilitation, Exercise and Nutrition Sciences, College of Allied Health Sciences, University of Cincinnati, Cincinnati, OH

²Department of Physical Therapy, College of Health Sciences, University of Delaware, Newark, DE

³Department of Rehabilitation Medicine, School of Medicine, Emory University, Atlanta, GA

Corresponding author:

Pierce Boyne, PT, DPT, PhD, NCS Health Sciences Building, room 267 3225 Eden Ave. Cincinnati, OH, 45267-0394 <u>Pierce.Boyne@uc.edu</u> 513-558-7499 (phone); 513-558-7474 (fax)

Key words: locomotion, gait, aerobic, exercise, dosing

Disclosures: The authors declare no conflicts of interest

Funding: This work was supported by grant R01HD093694 from the National Institutes of Health. AM was also supported by a Promotion of Doctoral Studies II Scholarship from the Foundation for Physical Therapy Research. Funding agencies had no role in the design, conduct or reporting of this research.

ABSTRACT

Background and Purpose: This meta-analysis quantified mean effects of moderate-to-vigorous intensity locomotor training (LT_{mv}) on walking outcomes in subacute and chronic stroke, and the magnitude of individual variability in LT_{mv} response.

Methods: Databases were searched for randomized trials comparing LT_{mv} with no intervention, non-gait intervention or low-intensity gait training. Comfortable gait speed (CGS), fastest gait speed (FGS), 6-minute walk distance (6MWT), walking activity (steps/day) and adverse effect/event (AE) data were extracted. Pooled estimates were calculated for mean changes within and between groups, the relative risk of different AEs, and the standard deviation of individual response (SD_{IR}) to LT_{mv} versus control groups, stratified by study chronicity where possible.

Results: There were 19 eligible studies (total N=1,096); 14 in chronic stroke (N=839) and 5 in subacute stroke (N=257). Compared with control interventions, LT_{mv} yielded significantly greater increases in CGS, FGS and 6MWT in both subacute and chronic stroke, with subacute studies showing significantly greater effect sizes for CGS, FGS and nearly 6MWT (p=0.054). In 4 studies reporting steps/day data, LT_{mv} was not significantly different from control interventions. In 14 studies reporting on AEs, there were no treatment-related serious AEs among 398 LT_{mv} participants. SD_{IR} estimates indicated significant individual response variability for CGS, nearly FGS (p=0.0501) and 6MWT.

Discussion and Conclusions: LT_{mv} improves mean walking capacity outcomes in subacute and chronic stroke and does not appear to have high risk of serious harm, but response magnitude varies between chronicity subgroups and individuals, and few studies have tested effects on daily walking activity or non-serious AEs.

1. INTRODUCTION

Clinical practice guidelines recommend moderate-to-vigorous intensity locomotor training (LT_{mv}) to improve walking speed and distance among persons with chronic stroke (>6 months post).¹ However, the effects of this approach have not been previously synthesized in subacute stroke, nor have they been quantitatively pooled with meta-analysis. Modern meta-analysis can improve the precision of effect estimation (narrower confidence intervals) by combining results across studies, and can support more valid inference than other synthesis methods.² Meta-analysis can also estimate the *magnitude* of treatment-related improvement on the scale of the original measurement, which facilitates interpretation of clinical meaning² and could inform LT_{mv} goal setting and progress monitoring.

While meta-analysis is most commonly used to pool mean treatment effects, it can also be used to pool estimates of response variability.³ This could be helpful to determine the need for prognostic studies of treatment response, since individual response prediction is only relevant if there is substantial response variability.⁴ Prior LT_{mv} studies have already begun exploring predictors of treatment response.^{e.g. 5-12} However, no previous studies have assessed the true amount of individual variability in LT_{mv} response, while controlling for variability due to measurement error.

Intervention studies in rehabilitation and other fields often appropriately report measures of within-group change variability (e.g. standard deviation of change within the experimental group).^{4,13,14} But these cannot be interpreted as measures of response variability because they will always be inflated by measurement error, to a varying degree depending on the test-reliability of the outcome measure in the study sample.^{4,13,14} Thus, within-group estimates of change variability alone will always overestimate the true variability in treatment response.

The standard deviation of individual response (SD_{IR}) overcomes this limitation by calculating response variability in the experimental group relative to a control group that is also subject to the same measurement error.^{4,13,14} Thus, an SD_{IR} greater than zero indicates true variability in response to an intervention, and the magnitude of the SD_{IR} estimates how much individual responses truly vary from the mean response. This could inform clinicians and patients/clients about the likely range of possible outcomes to expect from an intervention and the probability of a meaningful improvement.^{4,13,14} However, no previous studies have estimated the SD_{IR} for LT_{mv}. Also, few previous meta-analyses in any field have synthesized SD_{IR} estimates across studies,^{15,16} and this is a promising strategy to overcome the lower precision and statistical power when estimating measures of variability (e.g. SD_{IR}) rather than means.³

The current meta-analysis aimed to quantify mean effects of LT_{mv} on walking outcomes in subacute and chronic stroke, the risk of harms and the magnitude of true individual variability in LT_{mv} response. Using meta-regression,^{17,18} we also tested associations between effect sizes and study characteristics, including participant features, treatment parameters and risk of bias.

2. METHODS

2.1. Search Strategy

Studies were identified by searching electronic databases and scanning reference lists of articles from January to April of 2022. The database search included Pubmed, MEDLINE, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Physiotherapy Evidence Database (PEDro), and Academic Search Complete. Keywords and combinations are shown in the Appendix. This review was not pre-registered.

2.2. Eligibility Criteria

Types of studies

Randomized studies comparing LT_{mv} to a control group involving no intervention, non-gait intervention or low-intensity gait training, among stroke survivors. Reports had to be published in a peer-reviewed journal from 1/1/1995 to 3/1/2022 and the full text had to be available in English. When the same study was reported in multiple publications, the most complete report for each outcome was used for extraction.

Types of participants

Adult humans with a history of stroke. No restrictions were imposed based on stroke characteristics.

Types of interventions

LT_{mv} was defined as repetitive walking practice on a treadmill or overground with no more assistance than needed to enable safe practice (not to optimize kinematics), with either:

- 1) A moderate or higher mean aerobic intensity (>39% of heart rate reserve [HRR], peak oxygen consumption rate or peak work rate, or >63% of maximal heart rate);^{19,20} or
- 2) A focus on active training at faster than comfortable speed.

To be eligible for analysis, an LT_{mv} protocol had to include multiple training sessions, all intervention components had to be within the physical therapy scope of practice and an LT_{mv} group could not receive any additional primary intervention that the comparison group did not also receive (e.g. neuromuscular electrical stimulation, brain or spinal cord stimulation, rhythmic auditory stimulation, virtual reality, dual-task training, split-belt dual-speed training, resistance training, circuit training). However, the following did not count as additional primary interventions:

- 1) Assistance required to enable safe walking practice (e.g. fall protection harness, minimum necessary body weight support, minimum necessary physical or mechanical assist);
- Additional challenges to augment the intensity or difficulty of walking practice (e.g. incline/stair walking, resisted gait, limb weights, obstacles, gait perturbations, multi-directional gait, dual-task practice that only appeared to take up a small proportion of the experimental treatment time); or
- 3) Non-gait task practice that only appeared to take up a small proportion of the experimental treatment time.

Types of outcome measures

Walking capacity measures included comfortable gait speed (CGS) or fastest gait speed (FGS) over a short distance (e.g. 10m walk test), or a timed walking distance test (e.g. 6-minute walk test [6MWT]). Another outcome of interest was daily walking activity (mean steps per day), measured by an activity monitor. Only change scores from baseline to immediately post-intervention were included, because longer-term follow up time points are less consistent in the literature and more prone to missing data.

2.3. Eligibility Determination, Risk of Bias Assessment and Data Extraction

Two authors (OK and CM) independently assessed study eligibility, one author (AM) assessed each included outcome comparison with the Cochrane risk of bias 2 (RoB-2) instrument^{2,21} and another author (PB) performed RoB-2 assessment for adverse effect/event measures and resolved discrepancies and uncertainties. Data extraction was primarily performed by AM and PB, including: 1) study design and eligibility criteria; 2) characteristics of trial participants, like mean stroke chronicity (classified as subacute [< 6 months] or chronic [\geq 6 months]), ambulatory status (whether or not participants could walk short distances without continuous physical assistance from another person), and mean baseline outcome variables; 3) characteristics of the LT_{mv} and control interventions, like control type (intervention targeting lower limb function or not), LT_{mv} modes (treadmill and/or overground), mean LT_{mv} intensity (classified as moderate or vigorous),^{19,20} total LT_{mv} volume in hours, and whether participants were concurrently receiving usual care physical therapy; 4) outcomes, including mean changes and standard deviations of change in each group, between-group differences in mean change and corresponding variances; 5) adverse events in each group; and 6) overall risk of bias (low/some or high) for each comparison, which was categorized as high if more than one of the RoB-2 domains was rated high risk or if all five domains were rated at least some risk.

When mean LT_{mv} intensity was not reported, it was estimated from data provided, including peak intensity, starting intensity target and final intensity target. Moderate intensity was defined as 40-59% HRR or VO_{2peak} or 64-76% HR_{max}.^{19,20} Vigorous intensity was defined as 60-84% HRR or VO_{2peak} or 77-93% HR_{max}.^{19,20}

Outcome data extraction

Outcome data extraction used the methods described by the Cochrane Collaborative for mean differences,² prioritizing extraction of within-group mean changes and corresponding standard deviations of change (SD_{Δ}), standard errors, confidence intervals, p values or T statistics where available (in order of priority). When those were not available, we directly extracted estimates of the between-group difference in mean change with corresponding standard errors, confidence intervals, p values, T statistics or F statistics (in priority order). When multiple LT_{mv} or control groups in the same trial were eligible for analysis, we avoided data duplication by pooling data from those groups together with exact averaging weighted by group sample size.² For crossover studies, we extracted data from the initial parallel phase before any crossover.

When the best available measure to calculate variability was a p value inequality (e.g. p<0.05), the highest possible p value with one additional digit (e.g. p=0.049) was used to approximately impute the highest

variance (uncertainty) that would be consistent with the report.²² When the only available variability estimate was the standard deviation at baseline and post-intervention in each group, we calculated estimates for SD_{Δ} using the minimum repeated measures correlation from other eligible studies that reported all needed data.² Smaller repeated measures correlations are more conservative because they result in higher estimates for SD_{Δ} , reflecting greater uncertainty. These repeated measures correlations for the LT_{mv} and control groups (respectively) were: CGS, 0.70 and 0.62; FGS, 0.69 and 0.83; 6MWT, 0.65 and 0.88.

Adverse event data extraction

An adverse event was defined as an undesirable change in health status in a study participant that may or may not be related to study procedures, whereas an adverse *effect* was defined as an adverse event that had a reasonable possibility of being caused by the study intervention (e.g. occurred during training).² Adverse effects of interest were the number of participants experiencing any serious adverse event related to the study intervention²³ and the number of participants with new or increased musculoskeletal pain during training. The adverse event of interest was the number of randomized participants who experienced falls during study participation. We assumed that there were zero serious adverse effects in both groups if a study reported that no adverse events occurred. However, we did not make this assumption if adverse events were not mentioned, nor did we assume zero musculoskeletal pain effects or fallers unless those events were specifically reported.² If events were not reported by group they were recorded as missing.

Estimation of the standard deviation of individual response (SD_{IR}) from individual trials

 SD_{IR} was calculated for studies that reported separate estimates of change variability for each group. Since standard deviations like SD_{IR} have poor statistical properties,¹⁶ analyses were done using SD_{IR}^{2} (the variance of individual response) and its standard error:^{3,4,13-16}

$$SD_{IR}^{2} = SD_{\Delta LT_{mv}}^{2} - SD_{\Delta Control}^{2}$$
^[1]

Standard Error of
$$SD_{IR}^{2} = \sqrt{2\left(\frac{SD_{\Delta LT}mv^{4}}{[N_{LT}mv^{-1}]} + \frac{SD_{\Delta Control}^{4}}{[N_{Control}^{-1}]}\right)}$$
 [2]

Resulting estimates and confidence intervals were then converted to standard deviation units by taking the square root, while preserving any negative values.¹⁴⁻¹⁶

2.4. Statistical Methods

For outcome data, separate random-effects meta-analyses were performed for each estimate of interest (LT_{mv} – control mean change difference, SD_{IR}^2 and LT_{mv} within-group mean change) and for each outcome measure, using R^{24} and the 'meta' package,²⁵ with restricted maximum likelihood estimation of the between-study variance and Hartung-Knapp correction.

For adverse event data, separate random-effects meta-analyses estimated the relative risks (LT_{mv} / control incidence proportions) of each event/effect of interest (treatment-related serious adverse effects, treatment-related musculoskeletal pain and falls), using the 'meta' package,²⁵ with the exact Mantel-Haenszel method, restricted maximum likelihood estimation of the between-study variance and treatment arm continuity correction in studies with zero cell frequencies when calculating individual study results.

Between-study heterogeneity, meta-regression and assessment of publication bias

Between-study heterogeneity was assessed with l^2 , random effects model estimates of the betweenstudy standard deviation (τ) and p-values from the Cochran's Q test. Generally, l^2 values less than 30-40% may represent trivial heterogeneity, values between ~30-60% may represent moderate heterogeneity, and higher values may represent substantial heterogeneity.² Meta-regression models were attempted to explain some between-study variability by testing the association between study effect size and each independent variable of interest, including: stroke chronicity (subacute vs chronic), ambulatory status (all participants ambulatory vs some non-ambulatory), baseline level of the dependent variable, LT_{mv} mode (some overground training vs treadmill only), LT_{mv} intensity (vigorous vs moderate), LT_{mv} volume, control intervention (including vs not including any gait training), and risk of bias (high vs low/some). These meta-regressions were only attempted when there were at least 10 available studies and (for categorical independent variables) at least 3 studies in each category.² When there were sufficient studies, the primary analysis was stratified by stroke chronicity (the first meta-regression variable above) based on the aims of this study and established differences in effect sizes between subacute and chronic stroke studies.²⁶ Additional meta-regressions were only attempted within chronicity subgroups to avoid likely confounding.

The risk of publication bias was visually assessed with funnel plots and statistically estimated with Egger's test (for the continuous outcomes) or the score test (for the dichotomous adverse event data) when there were at least 10 studies.²

Between-group heterogeneity of (within-study) variance

It is common in meta-analysis to pool outcome variability estimates across groups within the same study, under the assumption that variability (in this case SD_{Δ}) does not differ between groups.² Our SD_{IR} analysis directly tested that assumption, since an SD_{IR} significantly different from zero indicates a significant between-group difference in SD_{Δ} . The SD_{IR} results suggested that the homogeneity of variance assumption was not plausible. Thus, we used separate SD_{Δ} estimates for each group in the meta-analyses involving mean changes. For studies where SD_{Δ} estimates were not available by group, we calculated them based on the between-group pooled variance estimate ($SD_{\Delta pooled}^2$) from that study and the overall SD_{IR} estimate pooled across studies for that outcome, using the formulas:

$$SD_{\Delta LT}{}_{mv} = \sqrt{\frac{SD_{\Delta pooled}{}^{2}(N_{total}-2) + SD_{IR}{}^{2}(0.5 \times N_{total}) - SD_{IR}{}^{2}}{(N_{total}-2)}}$$
[3]
$$SD_{\Delta Control} = \sqrt{\frac{SD_{\Delta pooled}{}^{2}(N_{total}-2) - SD_{IR}{}^{2}(0.5 \times N_{total}) + SD_{IR}{}^{2}}{(N_{total}-2)}}$$
[4]

When calculating the standard errors of the between-group differences in mean change, we were then able to use the heterogeneous variance formula [5] rather than the standard homogeneous variance formula [6]:

Standard Error of Mean Difference
$$(LT_{mv}\Delta - Control\Delta) = \sqrt{\frac{SD_{\Delta LT_{mv}}^2}{N_{LT_{mv}}} + \frac{SD_{\Delta Control}^2}{N_{Control}}}$$
[5]
Standard Error of Mean Difference $(LT_{mv}\Delta - Control\Delta) = \sqrt{\frac{SD_{\Delta pooled}^2}{N_{LT_{mv}}} + \frac{SD_{\Delta pooled}^2}{N_{Control}}}$ [6]

This heterogeneous variance formula [5] is more conservative in that it results in similar or higher standard error (uncertainty) than formula [6], depending on the magnitude of between-group imbalance in SD_{Δ}.

Imputation of missing outcome data

When a study did not provide results from an intent-to-treat analysis (i.e. when one or more randomized participants were not included in the analyses), missing outcome data were imputed using "strategy 1" from Ebrahim et al.²⁷ For participants with missing data, mean change was set at the value in the control group from the same study, and SD_A was set at the median control group SD_A across studies for that outcome measure (CGS, 0.09 m/s; FGS, 0.12 m/s; 6MWT, 32.6 m; daily walking activity, 860.5 steps/day). These values were calculated across subacute and chronic stroke studies because median control group SD_A was similar or identical between chronicity subgroups. The total mean change and SD_A scores within each treatment group for the full randomized (intent-to-treat) sample were estimated by combining the observed and imputed values using exact weighted averaging.² When calculating standard errors, participants with imputed data were not counted in the sample size to account for uncertainty in the imputed values and avoid artificial narrowing of the confidence intervals. Missing data imputation was not done for SD_{IR} analysis because it would bias the results towards larger SD_{IR}, since missing data were imputed with control group means. Missing data imputation was also omitted for adverse event analysis because it would tend to be anti-conservative by shrinking relative risk estimates towards no between-group difference.

Estimated proportions of responders

To estimate the proportion of participants with meaningful CGS, FGS, and 6MWT responses attributable to LT_{mv} , we modeled the distribution of individual net changes (i.e. individual change with LT_{mv} above and beyond the expected change with control interventions) as a normal curve. Separate distributions were generated for each outcome within each stroke chronicity subgroup. The mean of each distribution was set as the pooled estimate of the mean change difference (LT_{mv} – control) from the primary meta-analysis, and the SD was set as the pooled SD_{IR} (the estimate of the true individual variability in responsiveness).^{4,14} We then calculated the proportion of change differences in this modeled distribution that were above clinically important difference (CID) thresholds reported in the literature. CID thresholds ranged from 0.10 to 0.20 m/s for gait speed²⁸⁻³¹ and from 14 to 50 m for the 6MWT.³¹⁻³³

We also estimated the proportion of participants with meaningful changes during LT_{mv} (but not necessarily attributable to LT_{mv}) by setting the mean of each distribution as the pooled estimate of mean change within LT_{mv} groups, rather than the mean change difference between groups.⁴ This was done to provide estimates that may be more interpretable in the context of clinical practice, where individual patients/clients can be measured before and after LT_{mv} , but cannot perform both LT_{mv} and a control intervention in parallel.

3. RESULTS

3.1. Literature search results

The literature search identified 19 eligible studies (Supplemental Figure S1), with a combined sample size of 1,096 randomized participants (Table 1).^{7,8,12,34-49} Among these studies, 14 were in chronic stroke (N=839) and 5 were in subacute stroke (N=257). For two studies, additional data for outcomes of interest were found in other reports.^{50,51} Our literature search databases are publicly available (title/abstract screening: https://sysrev.com/u/5631/p/93708; full-text review: https://sysrev.com/u/5631/p/103118).

3.2. LT_{mv} versus control mean change differences

For the analysis of mean change differences, the three walking capacity outcomes (CGS, FGS and 6MWT) each showed significantly greater improvement with LT_{mv} versus control interventions in both subacute and chronic stroke (Table 2, Fig 1, Figs S2-S3). Subacute studies had significantly greater effect sizes than chronic studies for each of these outcomes except the 6MWT, which still showed a similar tendency (p=0.054). For daily walking activity, there were insufficient studies to stratify the analysis by study chronicity and no significant differences between LT_{mv} and control interventions (Fig S4).

For walking capacity outcomes, study chronicity explained 13-35% of the between-study variance in effect sizes (Table 2). After accounting for chronicity, significant heterogeneity remained for CGS and FGS (with l^2 of 60-61%) but not the 6MWT (with an l^2 of 24%). There were insufficient subacute stroke studies to pursue additional meta-regression analyses within that subgroup. In meta-regressions among the chronic stroke studies (Table S1), LT_{mv} mode explained the most between-study variance in CGS and FGS outcomes (54-69%), with significantly greater effect sizes in studies that included some overground gait training versus training only on a treadmill. A similar tendency was observed for 6MWT outcomes (R²=30%, p=0.06). Estimated LT_{mv} mean intensity (vigorous versus moderate) explained the most (residual) variance in 6MWT outcomes, but this variable could only be inferred for a subset of studies (11/14) and was not a statistically significant factor (p=0.08). There were insufficient studies to assess the influence of LT_{mv} intensity on CGS or FGS.

3.3. LT_{mv} versus control risk of harms

No treatment-related serious adverse effects were reported in any study groups, so relative risks could not be calculated for this effect (Table S2, Fig S5). There were no significant differences in the relative risk of treatment-related pain or the proportion of fallers between LT_{mv} and control groups (Fig S6-S7), and there were insufficient studies for any meta-regressions involving the adverse event measures.

3.4. Risk of bias assessments

The subgroup of chronic stroke comparisons judged to be at high risk of bias had significantly *lower* effect sizes for CGS (opposite the typical pattern of concern). Otherwise, there were no clear relationships between risk of bias and outcomes among the included comparisons (Table S1, Fig 1, Figs S2-S7). There was

also no statistically significant evidence of publication bias, nor any clear small study asymmetry trends in the funnel plots (Fig S8).

All adverse event comparisons were judged to be at high risk of bias for measurement of the outcome (domain 4). This was driven by more intensive monitoring of LT_{mv} groups in studies where control groups did not include a similar intervention volume (i.e. surveillance bias) and by lack of assessor blinding in all studies, where the study staff assessing adverse events appeared to be the same staff that were delivering the treatment, without any blinded adjudication.

3.5. Standard deviation of individual response (SD_{IR})

Sufficient information to calculate SD_{IR} was available in a subset of studies for each outcome (Table 3; Fig 2; Fig S9-S11). The pooled mean SD_{IR} was significantly greater than zero for CGS, almost FGS (p=0.0501) and 6MWT, but not for daily walking activity (p=0.52), which could only pool SD_{IR} data from two studies. There was significant between-study heterogeneity for CGS, FGS and daily walking activity (with I² of 70-86%), but insufficient studies for meta-regression to quantitatively explore its sources. The 6MWT had enough studies for the primary meta-regression but did not have significant heterogeneity (with I² of 27%) and study chronicity did not explain any of the between study variance in SD_{IR}² (R² of 0%).

3.6. Estimated proportions of responders

The estimated proportion of participants with at least small net changes attributable to LT_{mv} ranged across capacity measures from 36-68% in chronic stroke and from 71-82% in subacute stroke (Fig 3). Estimated proportions of responders with large net changes were 10-34% in chronic stroke and 36-53% in subacute stroke.

Pooled estimates of mean changes within LT_{mv} groups were also calculated to facilitate clinical interpretation (Table S3, Figs S12-S15). Based on these values, the estimated proportions of participants with at least small changes during LT_{mv} (not necessarily attributable to LT_{mv}) were 54-81% in chronic stroke and 99-100% in subacute stroke (Fig S16). Estimated proportions of responders with large changes were 21-50% in chronic stroke and 93-97% in subacute stroke.

4. DISCUSSION

This meta-analysis synthesized data on outcomes, risk of harms and response variability for LT_{mv} in subacute and chronic stroke recovery. Compared with no intervention, non-gait intervention or low-intensity gait training controls, LT_{mv} yielded significantly greater improvement in all walking capacity outcomes (CGS, FGS and 6MWT) in both subacute and chronic stroke, with subacute studies showing greater effect sizes (Table 2). Based on the smallest CID threshold for these outcomes (0.10 m/s for CGS/FGS²⁸⁻³¹ and 14 m for 6MWT³¹⁻³³), mean LT_{mv} gains were meaningfully better than control groups for the 6MWT in chronic stroke studies, and for all three walking capacity outcomes in subacute studies. These positive outcomes did not appear to be driven by individual study bias or publication bias. There were also no serious adverse effects related to treatment among 398 LT_{mv} participants, suggesting <0.25% risk of serious harms. These findings strengthen the recent clinical practice guideline recommendation that LT_{mv} should be used in chronic stroke,¹ and appear to warrant extending this recommendation to subacute stroke.

Nevertheless, SD_{IR} estimates indicated significant individual variability in LT_{mv} response for CGS, 6MWT and nearly FGS (p=0.0501). Each of these SD_{IR} estimates exceeded all CID thresholds (in SD units:^{4,16} 0.05-0.10 m/s for CGS/FGS²⁸⁻³¹ and 7-25 m for 6MWT³¹⁻³³), signifying a large and meaningful amount of individual response variability. Thus, clinicians and patients/clients should be aware that group-level LT_{mv} outcomes may not be very informative for expected individual changes. Future studies to improve prediction of individual LT_{mv} responses are strongly indicated.

Based on the mean change differences and SD_{IR} results, we estimated that LT_{mv} would elicit at least small meaningful gains in walking capacity outcomes (that would not otherwise occur with control interventions) for 36-68% of chronic stroke survivors and 71-82% of subacute stroke survivors (Fig 3). These estimates imply that LT_{mv} remains a powerful intervention despite response variability, producing meaningful walking capacity gains in 1 out of every 1-3 chronic stroke survivors treated and 1 out of every 1-2 subacute stroke survivors treated. When ignoring the control groups to mimic LT_{mv} delivery in clinical practice, we estimated that meaningful gains in walking capacity outcomes *during* LT_{mv} (but not necessarily attributable to LT_{mv}) would occur for 54-81% of chronic stroke survivors and 99-100% of subacute stroke survivors (Fig S16), at least in patients/clients similar to the included study samples. These percentages provide useful information for managing expectations in clinical practice.

While our findings indicate that LT_{mv} is efficacious for improving walking *capacity*, its effects on daily walking activity are less clear, as only four (out of 19) studies contributed to the pooled estimate of LT_{mv} versus control changes in steps/day (+260 [95%CI: -1,159 to 1,679]). In the absence of published CID thresholds for steps/day post-stroke, we interpret the point estimate of 260 steps/day as a small non-meaningful difference, but interpret the 95%CI bounds as very large differences. Thus, our current best estimate suggests LT_{mv} may not have a meaningful effect on daily walking activity, but this estimate is imprecise, and we cannot rule out very large beneficial or detrimental effects.

A lack of meaningful change in walking activity with LT_{mv} would be consistent with recent findings that gains in walking capacity do not automatically translate into gains in daily walking activity post-stroke.^{52,53} This limited translation may be due to the complex, multifactorial nature of daily walking activity, which requires sufficient walking capacity but can also be influenced by many other personal and environmental factors.⁵⁴⁻⁵⁷ The multifactorial nature of this measure may also explain the extremely large (albeit non-significant) individual variability we observed in walking activity changes from LT_{mv} (pooled SD_{IR}: 2,021 steps/day [95% CI: -7,135, 7,686]). Further studies assessing daily walking activity are needed to develop its CID benchmarks, more precisely estimate LT_{mv} effects, and augment the effects of LT_{mv} on this outcome.

Moderate between-study heterogeneity was present in the overall meta-analyses for all outcomes (l^2 , 40-68%; Table 2), matching our expectation that the magnitude of LT_{mv} effects likely depends on some study characteristics (e.g. participant sample, LT_{mv} delivery methods). Stroke chronicity explained 13-35% of this heterogeneity (across walking capacity outcomes) and there were enough chronic stroke studies to test how well other study factors explained residual heterogeneity within this subgroup (Table S1). In those analyses, studies that included some overground gait training had significantly greater improvements in CGS, FGS and nearly 6MWT (p=0.06), compared with studies involving only treadmill training. Like previous research,⁵⁸ this suggests that optimal LT_{mv} delivery may include both treadmill and overground training. Our results also hinted that vigorous LT_{mv} intensity may be superior to moderate intensity (like other research⁵⁹), but training intensity was difficult to determine from many of the reports, could only be tested for its association with 6MWT effect sizes and was not a significant factor (p=0.08).

Adverse event reporting was generally unsystematic across the included studies, and mostly appeared to reflect passive surveillance (i.e. relying on participants to self-report) without any specific queries or monitoring for events of interest. For example, several studies only reported that there were no adverse events, without specifying what types of events would have been reported had they occurred. This was less problematic for assessing serious adverse effects related to treatment, because it seemed safe to assume those would have been observed and reported if present, at least in the 14 (out of 19) studies that included some mention of adverse events. Thus, we are more confident in our estimate that <1 in 398 participants have serious adverse effects from LT_{mv}, and less confident in our relative risk estimates for non-serious treatment-related pain (1.91 [95%CI: 0.80, 4.54]) and non-serious falls outside of treatment (0.89 [95%CI: 0.57, 1.37]).

While imprecise and not statistically significant, these current point estimates imply that the risk of treatment-related pain (e.g. muscle/joint soreness) could be 91% higher with LT_{mv} versus control interventions (including no treatment), and that fall risk could be reduced by 11%. If accurate, these relative risks suggest that LT_{mv} could cause mild/moderate pain (that would not otherwise occur with control interventions) in 1 out of every 10 stroke survivors treated and could prevent falls in 1 out of every 35 (calculations² based on control group event rates in Table S2). From these non-serious event rates and the numbers needed to treat for meaningful walking capacity gains above, LT_{mv} benefits post-stroke appear to strongly outweigh its risks on average. Still, adverse event comparisons from all included studies were judged to have at least some concerns of overall bias, and high risk of bias for the outcome measurement domain (Figs S5-S7). This was primarily driven by unblinded adverse event assessment by the same personnel delivering treatment without any blinded adjudication. Thus, future LT_{mv} studies are needed to assess adverse events more systematically with larger samples and less risk of bias.

4.1. Strengths and Limitations

Methodological strengths of this meta-analysis include: the use of random effects models to account for plausible between-study heterogeneity and meta-regression to partially explain it; pooling outcomes using the original measurement scale (i.e. unstandardized effect sizes) for better clinical interpretability than using standard deviation units; pooling data on adverse events to better elucidate the balance between risk and

benefit; thorough assessment of risk of bias; pooled estimation of individual response variability in addition to mean effects; novel accounting for between-group differences in variance for more appropriate estimation of standard errors within individual studies; missing data imputation to estimate intent-to-treat effects for each study when not reported by the authors; and estimating proportions of responders to enhance interpretability of the results.

One limitation of this meta-analysis is that it did not account for the uncertainty associated with the estimation of between study variance (e.g. using Bayesian methods²²). Several additional limitations apply to the meta-regression analyses. Since meta-regression is observational, confounding can produce non-causal associations and can obscure causal effects. We used a principled approach to decrease the impact of confounding (e.g. only testing models with a reasonable number of studies, accounting for stroke chronicity in all models), but there were insufficient studies to thoroughly assess or control for other plausible confounders. Another meta-regression limitation is that many of the independent variables tested have variability at the individual level, but could only be extracted at the group level, which can produce misleading results (i.e. ecologic fallacy¹⁸). In addition, some meta-regression variables were difficult to ascertain for individual studies and required inference during data extraction.

5. Conclusions

LT_{mv} improves mean walking capacity outcomes in both subacute and chronic stroke and does not appear to have high risk of serious harm, but response magnitude varies between chronicity subgroups and individuals, and few studies have tested effects on daily walking activity or non-serious adverse events.

TABLES

Table 1. Charact		Months	000	500	CLARKE	Walking		
Study	Ν	post- stroke	CGS (m/s)	FGS (m/s)	6MWT (m)	activity (steps/d)	LT _{mv} group(s)	Control group(s)
Ada 2003	29	27.0	0.57	-	274	-	Fast TM+OG w AC, 45' 3d/wk, 4wk	Sham home exercise program
Ada 2013	102	20.3	0.50	0.67	234	-	Fast TM+OG w AC, 30', 3d/wk, 8-16wk*	No intervention
Aguiar 2020	22	47.5	1.01	1.52	403	-	TM @ 70% HRR, 40', 3d/wk, 12wk	OG @ <40% HRR, volume-matched
Awad 2016	33	19.5	0.68	0.95	277	-	Fast TM+OG, 36', 3d/wk, 12wk	TM @ comfortable speed, volume-matched
Eich 2004	50	1.4	-	0.42	109	-	TM @ 60% HRR w BWS _{PRN} , 30', 3d/wk, 6wk + UC	UC, volume-matched
Gjellesvik 2021	70	26.4	-	1.85	514	7862	TM HIIT bursts @ 90% HR _{max} , 38', 3d/wk, 8wk	Health education session
Globas 2012	38	64.8	0.72	0.90	268	-	TM @ 45->70% HRR, 40', 3d/wk, 13wk	UC elements, not volume-matched
Gordon 2013	128	12.3	-	-	238	-	OG @ 73% HR _{max} , 30', 3d/wk, 12wk	Light massage
Holleran 2015	14	>6	-	-	199	-	TM+OG @ 75% HRR w AC, 40', 3d/wk, 4wk	TM+OG @ 35% HRR, volume & speed- matched
Hornby 2016	33	3.3	0.34	0.47	124	1863	TM+OG @ 75% HRR w BWS _{PRN} , A _{PRN} & AC, 40', 4d/wk, 10wk	UC, volume-matched
Hornby 2019	97	38.9	0.51	0.66	201	2951	TM+OG @ 75% HRR w BWS _{PRN} & AC^, 40', 4d/wk, 8wk	TM+OG @ 35%HRR w BWS _{PRN} & AC, volume- matched
lvey 2011	51	>6	0.54	-	197	-	TM @ 45->65% HRR w BWS _{PRN} , 40', 3d/wk, 24wk	UC elements, volume- matched
lvey 2015	51	38.9	0.41	0.57	208	5401	TM @ 45->83% HRR, 30', 3d/wk, 24wk	TM @ <50% HRR, volume-matched + 20'/session
Klassen 2020	75	0.9	0.42	-	132	-	TM+OG @ 40->60+% HRR w BWS _{PRN} & AC + UC, 60-120' [†] , 5d/wk, 4wk	UC, volume matched [†]
Kuys 2011	30	1.7	0.47	0.63	200	-	TM @ 40->60% HRR, 30', 3d/wk, 6wk + UC	UC, not volume- matched
Luft 2008	113	53.6	-	0.69	198	-	TM @ 45->60% HRR, 40', 3d/wk, 24wk	UC elements, volume- matched
Macko 2005	61	36.9	0.65	0.86	244	-	TM @ 45->65% HRR, 40', 3d/wk, 24wk	UC elements, volume- matched
Moore 2010	30	>6	0.56	0.77	192	-	TM @ 83% HR _{max} w BWS _{PRN} , 40', 2-5d/wk, 4wk	No intervention (but UC until plateau just prior to study for both groups)
Pohl 2002	69	3.8	-	0.64	-	-	Max-speed TM HIIT, 30', 3d/wk, 4wk + UC	Low speed TM w assis & BWS _{PRN} + UC; or UC only; [‡] volume-matched

Values are N randomized and baseline means across participants. @, target intensity; ->, progression across sessions; 6MWT, 6-minute walk test; AC, additional (gait) challenges; BWS_{PRN}, body weight support only if needed to enable practice; CGS, comfortable gait speed; d, day; FGS, fast gait speed; HIIT, high-intensity interval training; HR_{max}, peak/max heart rate; HRR, heart rate reserve; LT_{mv}, moderate-to-vigorous intensity locomotor training; TM, treadmill training; OG, overground training; UC, usual care physical therapy; w, with; wk, week; *Two LT_{mv} groups were combined; one with 8 weeks of training and the other with 16; ^Two LT_{mv} groups were combined; one with AC and the other without; [†]Two LT_{mv} groups were combined; one with 60' and one with 120' sessions (the control group had 60' sessions); [‡]Two control groups were combined

		Mean Change Di	fference		etween-st eterogene		
	N studies (total N)	Estimate [95%Cl]	P- value	SD (τ)	²	P- value*	R ²
Comfortable gait speed, m/s	13 (652)	0.08 [0.04, 0.12]	0.0017	0.054	67.6%	0.0002	-
Chronic stroke studies	10 (514)	0.06 [0.01, 0.10]	0.0173	0.044	65.1%	0.0022	-
Subacute stroke studies	3 (138)	0.16 [0.12, 0.19]	0.0022	0.044	0.0%	0.9144	-
Subacute vs chronic stroke	13 (652)	0.10 [0.01, 0.18]	0.0263	0.044	59.7%	0.0042	34.6%
Fastest gait speed, m/s	14 (799)	0.10 [0.04, 0.16]	0.0026	0.065	62.9%	0.0008	-
Chronic stroke studies	10 (617)	0.07 [0.02, 0.13]	0.0126	0.060	59.7%	0.008	-
Subacute stroke studies	4 (182)	0.21 [0.01, 0.41]	0.046	0.060	54.8%	0.0846	-
Subacute vs chronic stroke	14 (799)	0.14 [0.01, 0.26]	0.0362	0.060	61.4%	0.0019	13.3%
6-minute walk test, m	18 (1027)	37 [29, 46]	<0.0001	10.9	40.1%	0.0409	-
Chronic stroke studies	14 (839)	33 [24, 42]	<0.0001	8.8	22.3%	0.2117	-
Subacute stroke studies	4 (188)	51 [26, 77]	0.0077	8.8	29.2%	0.2371	-
Subacute vs chronic stroke	18 (1027)	18 [-0, 37]	0.0539	8.8	23.8%	0.1781	34.4%
Daily walking activity, steps/day	4 (251)	260 [-1159, 1679]	0.6008	477	49.8%	0.1125	-

explained by the contrast variable, and R^2 is the % of between-study heterogeneity explained by contrast variable. LT_{mv}, moderate-to-vigorous intensity locomotor training; I^2 , % of variance attributed to between-study heterogeneity; SD, standard deviation (between studies); *p-value for between-study heterogeneity is from Cochran's Q test

Table 3. Standard Deviations of Ind	lividual Resp	oonse (SD _{IR}) to LT _{mv}					
		Mean Change Diffe	erence		tween-st terogene		
	N studies (total N)	Estimate [95%CI]	P- value	SD (τ)	l ²	P- value*	R ²
Comfortable gait speed, m/s	9 (406)	0.11 [0.00, 0.15]	0.0489	0.11	69.8%	0.0009	-
Fastest gait speed, m/s	8 (394)	0.14 [-0.00, 0.20]	0.0501	0.14	74.6%	0.0003	-
6-minute walk test, m	11 (467)	41 [27, 51]	0.0025	22	27.2%	0.1853	-
Chronic stroke	8 (357)	42 [29, 52]	0.0025	25	0.0%	0.4825	-
Subacute stroke	3 (110)	38 [-70, 89]	0.4303	25	70.3%	0.0345	-
Subacute vs chronic stroke	11 (467)	-18 [-52, 46]	0.7707	25	33.5%	0.1401	0.0%
Daily walking activity (steps/day)	2 (90)	2021 [-7135, 7686]	0.5185	2394	86.4%	0.0067	-
Values were converted from SD _{IR} ² un standard deviations (SD). For the row residual heterogeneity not explained l explained by contrast variable. LT _{mv} , between-study heterogeneity; *p-valu	with a contra by the contras moderate-to-v	ast (in <i>italics</i>), between st variable, and R ² is th vigorous intensity locor	-study he ie % of be notor trair	terogene etween-s ning; I², %	ity statisti tudy hete ⁄₀ of varia	cs are for rogeneity	

		Mean Change Diff	ference		etween-stu eterogene	ity	
Within Chronic Stroke Studies	N studies (total N)	Estimate [95%CI]	P- value	SD (τ)	²	P- value*	R ²
Comfortable gait speed (CGS), m/s	10 (514)	0.06 [0.01, 0.10]	0.0173	0.044	65.1%	0.0022	-
Mean baseline CGS (each 0.1 m/s \uparrow)	10 (514)	-0.01 [-0.04, 0.03]	0.5588	0.053	69.9%	0.0008	0.0%
Treadmill-only LT _{mv}	6 (253)	0.02 [-0.03, 0.07]	0.3826	0.028	30.1%	0.2092	-
Some overground LT _{mv}	4 (261)	0.11 [0.06, 0.16]	0.0068	0.028	7.0%	0.3579	-
Some overground LT _{mv} vs treadmill only	10 (514)	0.09 [0.03, 0.15]	0.0100	0.028	23.9%	0.2305	68.5%
Planned LT_{mv} volume (each 10 hour \uparrow)	10 (514)	-0.02 [-0.06, 0.01]	0.2156	0.043	60.1%	0.0101	23.5%
Control with no gait training	5 (250)	0.07 [0.03, 0.11]	0.0093	0.054	0.0%	0.7988	-
Control with some gait training	5 (264)	0.04 [-0.06, 0.15]	0.3266	0.054	83.4%	< 0.0001	-
Control with vs without gait training	10 (514)	-0.03 [-0.12, 0.07]	0.5432	0.054	72.1%	0.0004	0.0%
Low/some risk of bias	6 (321)	0.09 [0.03, 0.14]	0.0086	0.032	49.3%	0.0794	-
High risk of bias	4 (193)	0.01 [-0.07, 0.08]	0.7612	0.032	16.3%	0.3098	-
High vs low/some risk of bias	10 (514)	-0.08 [-0.16, -0.00]	0.0423	0.032	42.0%	0.0875	58.9%
Fastest gait speed (FGS), m/s	10 (617)	0.07 [0.02, 0.13]	0.0126	0.060	59.7%	0.008	-
Mean baseline FGS (each 0.1 m/s 1)	10 (617)	-0.01 [-0.02, 0.01]	0.2759	0.058	61.8%	0.0073	3.0%
Treadmill-only LT _{my}	7 (385)	0.04 [-0.01, 0.10]	0.1126	0.040	24.7%	0.2407	-
Some overground LT _{mv}	3 (232)	0.14 [-0.00, 0.28]	0.0505	0.040	50.1%	0.1350	-
Some overground LT_{mv} vs treadmill only	10 (617)	0.10 [0.01, 0.19]	0.0312	0.040	34.7%	0.1405	54.2%
Planned LT_{mv} volume (each 10 hour \uparrow)	10 (617)	-0.03 [-0.07, 0.01]	0.1434	0.046	48.8%	0.0483	39.9%
Control with no gait training	5 (353)	0.08 [0.02, 0.14]	0.0167	0.065	2.3%	0.3936	-
Control with some gait training	5 (264)	0.06 [-0.06, 0.19]	0.2396	0.065	78.0%	0.0011	-
Control with vs without gait training	10 (617)	-0.02 [-0.13, 0.10]	0.7306	0.065	67.5%	0.0018	0.0%
Low/some risk of bias	7 (475)	0.10 [0.02, 0.17]	0.0183	0.051	63.2%	0.0123	-
High risk of bias	3 (142)	0.02 [-0.03, 0.07]	0.2616	0.051	0.0%	0.9176	-
High vs low/some risk of bias	10 (617)	-0.08 [-0.20, 0.05]	0.1889	0.051	53.9%	0.0266	26.2%
6-minute walk test (6MWT), m	14 (839)	33 [24, 42]	< 0.0001	8.8	22.3%	0.2117	-
Mean baseline 6MWT (each 10 m 1)	14 (839)	0[-1, 1]	0.8349	9.4	28.1%	0.1612	0.0%
Treadmill-only LT _{my}	8 (436)	26 [15, 37]	0.0008	7.1	0.0%	0.5116	-
Some overground LT _{mv}	6 (403)	41 [26, 57]	0.0010	7.1	20.7%	0.2775	-
Some overground LT_{mv} vs treadmill only	14 (839)	15 [-1, 32]	0.0622	7.1	4.7%	0.399	29.6%
Moderate LT _{mv} intensity	6 (397)	25 [12, 37]	0.0036	4.9	0.0%	0.5609	-
Vigorous LT _{mv} intensity	5 (278)	41 [22, 60]	0.0038	4.9	19.9%	0.2876	-
Vigorous vs moderate intensity	11 (675)	16 [-2, 34]	0.0791	4.9	0.0%	0.444	71.6%
Planned LT_{mv} volume (each 10 hour \hat{T})	14 (839)	-6 [-11, 0]	0.0600	4.9	0.6%	0.4395	66.0%
Control with no gait training	8 (561)	29 [17, 41]	0.0008	5.5	25.1%	0.2286	-
Control with some gait training	6 (278)	42 [26, 58]	0.0009	5.5	0.0%	0.5378	-
Control with vs without gait training	14 (839)	13 [-5, 32]	0.1431	5.5	10.8%	0.3371	58.1%
Low/some risk of bias	10 (646)	36 [25, 47]	< 0.0001	8.9	35.3%	0.1259	-
High risk of bias	4 (193)	22 [5, 40]	0.0261	8.9	0.0%	0.7676	-
High vs low/some risk of bias	14 (839)	-14 [-35, 7]	0.1835	8.9	20.9%	0.2323	0.0%

For rows with contrasts (rows in *italics*), between-study heterogeneity statistics are for residual heterogeneity not explained by the contrast variable, and R² is the % of between-study heterogeneity explained by contrast variable. LT_{mv}, moderate-to-vigorous intensity locomotor training; I², % of variance attributed to between-study heterogeneity; SD, standard deviation; *p-value for between-study heterogeneity is from Cochran's Q test;

Table S2. LT _{mv} Versus Co	ntrol Risks o N studies (total N)	N eve	nts / N ants (%)		Relative Risk (LT _{mv} / Control)			tween- teroge	-
	reporting on event	LT _{mv}	Control	N studies (total N)*	Estimate [95%Cl]	P- value	SD (τ)	l ²	P- value*
Treatment-Related SAE	14 (758)	0 / 398 (0.0%)	0 / 360 (0.0%)	0 (0)	-	-	-	-	-
Treatment-Related Pain	7 (350)	56 / 182 (30.8%)	19 / 168 (11.3%)	4 (190)	1.91 [0.80, 4.54]	0.1433	0.49	0%	0.4060
Falls	6 (287)	43 / 172 (25.0%)	30 / 115 (26.1%)	5 (269)	0.89 [0.57, 1.37]	0.5861	0.21	12%	0.3365
*Studies with no events in e	either group d	lo not contri	bute any in	formation abo	out relative risks bet	ween grou	ups. LT	_{nv} , mod	erate-to-

vigorous intensity locomotor training; I², % of variance attributed to between-study heterogeneity; *p-value for between-study heterogeneity is from Cochran's Q test; SAE, serious adverse effect;

		Mean Change V	Nithin	B	etween-st	tudy	
			os	h	eterogen	eity	
	N studies (total N)	Estimate [95%CI]	P- value	SD (τ)	l ²	P- value*	R ²
Comfortable gait speed, m/s	13 (652)	0.16 [0.08, 0.24]	0.0008	0.126	96.9%	<0.0001	-
Chronic stroke studies	10 (514)	0.11 [0.06, 0.15]	0.0003	0.073	77.0%	<0.0001	-
Subacute stroke studies	3 (138)	0.36 [-0.00, 0.73]	0.0512	0.073	93.3%	<0.0001	-
Subacute vs chronic stroke	13 (652)	0.25 [0.13, 0.37]	0.0007	0.073	89.0%	<0.0001	66.4%
Fastest gait speed, m/s	14 (799)	0.20 [0.08, 0.33]	0.004	0.196	90.4%	<0.0001	-
Chronic stroke studies	10 (617)	0.12 [0.06, 0.18]	0.0018	0.122	82.3%	<0.0001	-
Subacute stroke studies	4 (182)	0.43 [-0.02, 0.87]	0.0546	0.122	89.4%	<0.0001	-
Subacute vs chronic stroke	14 (799)	0.31 [0.11, 0.52]	0.0057	0.122	86.5%	<0.0001	61.6%
6-minute walk test, m	18 (1027)	66 [46, 86]	<0.0001	38.3	95.5%	<0.0001	-
Chronic stroke studies	14 (839)	50 [37, 62]	<0.0001	23.8	74.7%	<0.0001	-
Subacute stroke studies	4 (188)	127 [61, 193]	0.0088	23.8	95.3%	<0.0001	-
Subacute vs chronic stroke	18 (1027)	77 [45, 110]	0.0001	23.8	87.1%	<0.0001	61.5%
Daily walking activity, steps/day	4 (251)	270 [-1518, 2057]	0.664	937	72.2%	0.0129	-

explained by the contrast variable, and R² is the % of between-study heterogeneity explained by contrast variable. LT_{mv}, moderate-to-vigorous intensity locomotor training; I², % of variance attributed to between-study heterogeneity; SD, standard deviation; *p-value for between-study heterogeneity is from Cochran's Q test

FIGURES

Figure 1. Mean change (Δ **) differences for LT**_{mv} versus control interventions: 6-minute walk test. Results from a random (mixed) effects meta-analysis stratified by stroke chronicity. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (14-50 m).³¹⁻³³ Risk-of-bias assessment was performed using the RoB-2 tool, yielding an overall (O) judgment based on the following domains: R, Bias arising from the randomization process; D, Bias due to deviations from intended intervention; Mi, Bias due to missing outcome data; Me, Bias in measurement of the outcome; S, Bias in selection of the reported result. N, number of participants randomized; N_{imp}, number of randomized participants not included in the reported analysis whose outcomes were imputed; SD Δ , standard deviation of change; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study and subgroup to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.

	Ν	Ν	Nimp	Nimp	Mean∆	Mean∆	SDΔ	SD∆																		Ri	isk (of B	ias	
Study	LTmv	Ctrl	LTmv	/ Ctrl	LTmv	Ctrl	LTmv	Ctrl		М	ean 🛆 l	Differe	ence	: LT _n	_{nv} - C	trl		Es	timat	te S	SE	95%	CI	Weight	0	R	D	М	i Me	e S
Chronic Stroke																														
Ada 2003	14	15	3	1	81	13	73	26					-						6	8 23	3.0 [20; 1	15]	2.9%	-	+	+	X	+	
Ada 2013	68	34	0	0	46	19	52	41				<u> </u>							2	6 9	9.4	[8;	45]	8.9%	+	+	+	+	+	
Aguiar 2020	11	11	0	0	48	15	58	29	-	_			-						3	3 19	9.6	[-8;	74]	3.7%	-	+	+	X	+	+
Awad 2016	16	17	0	3	87	36	69	54		-	_								5	1 22	2.4	[5;	97]	3.0%	-	-	+	•	+	-
Gjellesvik 2021	36	34	0	0	41	13	61	46		-		-	-						2	8 12	2.9	[3;	54]	6.5%	+	+	+	+	+	-
Globas 2012	20	18	2	0	52	5	46	25			-								4	8 12	2.3	[23;	73]	6.8%	-	+	+	+	X	, 😑
Gordon 2013	64	64	0	0	43	9	64	50				-	-						3	4 10).2	[14;	54]	8.3%	-	•	+	•	+	-
Holleran 2015	7	7	1	1	57	13	55	17	-	-	_		-						4	4 23	3.7	[-9;	97]	2.7%	-	•	+	•	-	, 😑
Hornby 2019	64	33	0	0	90	34	66	37				÷			-				5	6 10).5	[35;	77]	8.1%	+	+	+	+	+	
lvey 2011	26	25	7	6	30	8	45	25		+									2	3 11	.9	[-1;	47]	7.1%	×	•	X	X	X	, 😑
lvey 2015	24	27	6	12	50	32	54	49					-						1	8 18	3.0	[-18;	55]	4.2%	×	•	X	X	-	, 😑
Luft 2008	57	56	20	22	21	7	46	31		+-		- :							1	4 9	9.2	[-4;	32]	9.1%	-	+	+	X	+	
Macko 2005	32	29	7	9	40	6	62	46			_		-	_					3	4 16	6.2	[1;	66]	4.8%	×	•	X	X	+	
Moore 2010	15	15	5	5	21	23	74	67	←	•	_		-	_					-	2 31	.6	[-69;	64]	1.7%	×	+	X	X	X	
Subgroup estimate	454	385																	3	3		[24;	42]	77.8%						
Heterogeneity: $I^2 = 22\%$,	τ = 8.8, μ	0 = 0.2	2117									-																		
Test for effect in subgroup	$t_{13} = 7$.96 (p	< 0.00	01)																										
Subacute Stroke																														
Eich 2004	25	25	0	0	91	56	44	33			_		-						3	5 10).9	[13;	57]	7.8%	-	+	+	+	X	, 😑
Hornby 2016	16	17	1	0	113	30	111	32					-					→	8	3 29	.8 [23; 1	44]	1.8%	+	+	+	+	+	-
Klassen 2020	50	25	1	1	176	117	47	22											5	8 8	3.0 [.]	[42;	74]	10.1%	+	+	+	+	+	-
Kuys 2011	15	15	2	0	113	60	82	46			_						-		5	3 25	5.7	0;1	06]	2.4%	+	+	+	•	+	-
Subgroup estimate	106	82									-				-				5	1		[26;	77]	22.2%						
Heterogeneity: $I^2 = 29\%$,	τ = 8.8, μ	0 = 0.2	2371																				-							
Test for effect in subgroup	$t_3 = 6.4$	42 (p	= 0.007	77)																										
Overall estimate	560	467																	3	7	I	[29;	46]	100.0%	Γ	⊗ ⊦	ligh i	risk o	f bia	s
Heterogeneity: $I^2 = 40\%$,	$\tau = 10.9$,	p = 0	.0409																				-			- s	Some	e con	cerns	s
Residual heterogeneity: I				0.1781					-20	0	20	40	60	D	80	100) ·	120								+ L	_ow r	isk o	f bias	3
Test for overall effect: t_{17}											6-Mir	nute V	Valk [.]	Test	(m)										_					
Test for subgroup differen		16) = 4	4.33 (p	= 0.053	39)										()															

Figure 2. Variance of individual response (SD_{IR}²): **6-minute walk test.** Results from a random (mixed) effects meta-analysis stratified by stroke chronicity. SD_{IR} estimates and 95%CI can be obtained by taking the square root of the values in this figure. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (14-50 m),³¹⁻³³ converted to SD_{IR}² units by halving and squaring (49-625 m²).^{4,16} N, number of participants analyzed; SD Δ , standard deviation of change; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study and subgroup to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.

Study	N LTmv		SD∆ LTmv		SD _{IB} ² E	Estimate	SE	95%C	Weight
Obvenie Otvelse									_
Chronic Stroke			70	07		4474		L 101 0710	0.00/
Ada 2003	11	14	70	27			2209.9	L	
Ada 2013	68	34	52	41		1015	623.1	[-221; 2252]	
Aguiar 2020	11	11	58	29			1550.7	L / .	
Awad 2016	16	14	69	58			2182.5	L / .	
Globas 2012	18	18	45	25		1363	715.3	[-91; 2816]	
Holleran 2015	6	6	57	19				[-1719; 7495]	
Hornby 2019	64	33	66	37		2975		[1280; 4670]	
lvey 2015	18	15	59	60			1817.8	[-3793; 3622]	
Subgroup estimate	212				· · · · · · · · · · · · · · · · · · ·	1780		[865; 2695]	75.1%
Heterogeneity: $I^2 = 0\%$, τ		/							
Test for effect in subgroup	o: $t_7 = 4.6$	60 (p =	= 0.002	5)					
Subacute Stroke									
Eich 2004	25	25	44	33		829	626.5	[-430; 2089]	22.8%
Hornby 2016	15	17	113	32	+>	11745	4839.8	[1861; 21629]	0.6%
Kuys 2011	13	15	85	46		5109	3056.1	[-1173; 11391]	1.5%
Subgroup estimate	53	57				1460		[-4947; 7867]	24.9%
Heterogeneity: $I^2 = 70\%$,	$\tau = 623.4$, p = (0.0345						
Test for effect in subgroup	o: $t_2 = 0.9$)8 (p =	= 0.4303	3)					
Overall estimate	265	202			•	1649		[731; 2567]	100.0%
Heterogeneity: $I^2 = 27\%$,	$\tau = 477.8$, p = 0	0.1853						
Residual heterogeneity: I				= 0.140	-2000 0 2000 4000 6000 8000 1000012000				
Test for overall effect: t_{10}					6-Minute Walk Test (m) ²				
Test for subgroup differen				0.7707					
		, ,,	- N-						

Figure 3. Estimated proportions of participants with meaningful gains attributable to LT_{mv}. Graphs show the estimated distributions of individual differences in response (Δ_{net}) to LT_{mv} versus control (i.e. how much more [or less] individuals are expected to improve with LT_{mv} relative to control interventions), based on the meta-analysis results. Separate distributions were calculated for each outcome measure (from left to right: comfortable gait speed, fastest gait speed, 6-minute walk test) and for each stroke chronicity subgroup (top panel, chronic; bottom panel, subacute). The mean of each distribution is the meta-analysis estimate of the mean Δ difference (LT_{mv} – control), and the SD of each distribution is the meta-analysis estimate of the SD_{IR} (the estimate of the true individual variability in responsiveness).^{4,14} Reported probabilities (P) are the % of individual net changes that were at or above different clinically important difference thresholds from the literature. These thresholds ranged from 0.10 m/s (small) to 0.20 m/s (large) for gait speed²⁸⁻³¹ and from 14 m (small) to 50 m (large) for the 6-minute walk test.³¹⁻³³




Figure S1. PRISMA Flow Diagram.




Figure S2. Mean change (Δ **) differences for LT**_{mv} **versus control interventions: Comfortable gait speed.** Results from a random (mixed) effects meta-analysis stratified by stroke chronicity. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (0.1-0.2 m/s). Risk-of-bias assessment was performed using the RoB-2 tool, yielding an overall (O) judgment based on the following domains: R, Bias arising from the randomization process; D, Bias due to deviations from intended intervention; Mi, Bias due to missing outcome data; Me, Bias in measurement of the outcome; S, Bias in selection of the reported result. N, number of participants randomized; N_{imp}, number of randomized participants not included in the reported analysis whose outcomes were imputed; SD Δ , standard deviation of change; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study and subgroup to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.

	Ν				Mean∆	Mean∆	SD∆	SD∆								k of			_
Study	LTmv	Ctrl	LTmv	Ctrl	LTmv	Ctrl	LTmv	Ctrl	Mean \triangle Difference: LT _{mv} - Ctrl Es	stimate	SE	95%CI	Weight	0	R	D	Mi	Me S	\$
Chronic Stroke																			
Ada 2003	14	15	3	1	0.15	0.04	0.18	0.07		0.11 0	0.057	[-0.01; 0.23]	6.1%	-	+	+	X	+ (
Ada 2013	68		0	0	0.14	0.06	0.18					[0.03; 0.14]	10.1%	+	+	+	+	+	5
Aguiar 2020	11	11	0	0	0.09	0.14	0.17	0.18	← ■ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓			[-0.21; 0.11]	4.5%	-	+	+	X	+ (E I
Awad 2016	16	17	0	3	0.20	0.12	0.13	0.15				[-0.02; 0.18]	6.9%	•	•	+	ē	+ (5
Globas 2012	20	18	2	0	0.06	0.00	0.09	0.08	<u>_</u>			[0.01; 0.12]	10.1%	•	+	+	+	×	5
Hornby 2019	64	33	0	0	0.17	0.02	0.16	0.07		0.15 0	0.023	[0.10; 0.19]	10.9%	+	+	+	+	+	•
lvey 2011	26	25	7	6	0.07	0.00	0.15	0.11				[-0.02; 0.15]	8.2%	×	-	X	X	8	•
lvey 2015	24	27	6	11	0.02	0.06	0.11	0.10		-0.04 0	0.035	[-0.11; 0.03]	9.2%	×	-	X	X	•	•
Macko 2005	32	29	7	9	0.11	0.09	0.17	0.14	_	0.02 0	0.047	[-0.08; 0.11]	7.4%	×	-	X	X	+ (•
Moore 2010	15	15	5	5	0.05	0.05	0.19	0.16		0.00 0	0.078	[-0.16; 0.16]	4.2%	×	+	X	X	8	•
Subgroup estimate	290	224								0.06		[0.01; 0.10]	77.6%						
Heterogeneity: $I^2 = 65\%$, τ	= 0.044	I, p =	0.0022																
Test for effect in subgroup	: t ₉ = 2.9	91 (p :	= 0.017	3)															
Subacute Stroke																			
Hornby 2016	16	17	1	0	0.26	0.09	0.22	0 00		0 17 0	060	[0.05; 0.29]	5.8%	+	+	+	+	+ (
Klassen 2020	50		i	1	0.50	0.35	0.13					[0.10; 0.19]	10.8%	<u> </u>	4	4	+	<u> </u>	<u>.</u>
Kuys 2011	15		2	o	0.25	0.09	0.21					[0.04; 0.29]	5.8%	÷	+	+	ě	÷ (<u>.</u>
Subgroup estimate	81		-	Ū	0.20	0.00	0.21	0.07		0.16		[0.12; 0.19]	22.4%				•		· .
Heterogeneity: $I^2 = 0\%$, $\tau =$			9144							0.10		[0.12, 0.10]	2217/U						
Test for effect in subgroup				22)															
Overall estimate		281							• • • • • • • • • • • • • • • • • • •	0.08		[0.04; 0.12]	100.0%		👌 Hię	gh ris	k of	bias	
Heterogeneity: $I^2 = 68\%$, τ	= 0.054	l, p =	0.0002											•	So	me c	conce	erns	
Residual heterogeneity: I2				= 0.004	42				-0.2 -0.1 0 0.1 0.2 0.3 0.4					•	Lo	w ris	k of l	bias	
Test for overall effect: t_{12} =									Comfortable Gait Speed (m/s)										
Test for subgroup difference	ce: F(1,1	11) = 6	6.58 (p	= 0.02	63)														

Figure S3. Mean change (Δ) **differences for LT**_{mv} **versus control interventions: Fastest gait speed.** Results from a random (mixed) effects meta-analysis stratified by stroke chronicity. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (0.1-0.2 m/s). Risk-of-bias assessment was performed using the RoB-2 tool, yielding an overall (O) judgment based on the following domains: R, Bias arising from the randomization process; D, Bias due to deviations from intended intervention; Mi, Bias due to missing outcome data; Me, Bias in measurement of the outcome; S, Bias in selection of the reported result. N, number of participants randomized; N_{imp}, number of randomized participants not included in the reported analysis whose outcomes were imputed; SD Δ , standard deviation of change; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study and subgroup to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.

	Ν	Ν	Nimp	Nimp	Mean∆	Mean∆	SDΔ	SD∆							Ris	sk o	f Bia	is
Study	LTmv	Ctrl	LTm	Ctrl	LTmv	Ctrl	LTmv	Ctrl	Mean Δ Difference: LT _{mv} - Ctrl	Estimate	SE	95%CI W	Veight	0	R	D	Mi	Me S
Chronic Stroke																		
Ada 2013	68	34	0	0	0.17	0.06	0.23	0.12		0.11 0	0.035	[0.05; 0.18]	10.6%	+	+	+	+	+ -
Aguiar 2020	11	11	0	0	-0.05	0.02	0.22	0.16	← ■	-0.07 0	0.082	[-0.24; 0.10]	5.2%	-	+	+	×	+ +
Awad 2016	16	17	0	3	0.19	0.11	0.24	0.11		0.08 0	0.067	[-0.06; 0.22]	6.6%	•	-	+	-	+ -
Gjellesvik 2021	36	34	0	0	0.09	0.05	0.35	0.33		0.04 0	0.081	[-0.12; 0.20]	5.3%	+	+	+	-	+ -
Globas 2012	20	18	2	0	0.11	-0.02	0.12	0.08		0.13 0	0.036	[0.05; 0.20]	10.5%	•	+	+	+	8 -
Hornby 2019	64	33	0	0	0.27	0.07	0.21	0.12		0.20 0	0.033	[0.13; 0.26]	10.8%	+	+	+	+	+ -
lvey 2015	24	27	8	14	0.06	0.04	0.09	0.14		0.02 0	0.044	[-0.07; 0.11]	9.4%	×	-	X	X	
Luft 2008	57	56	20	22	0.08	0.05	0.19	0.15		0.03 0	0.040	[-0.05; 0.11]	9.8%	•	+	+	X	+ -
Macko 2005	32	29	7	9	0.13	0.13	0.25	0.21		0.00 0	0.070	[-0.14; 0.14]	6.3%	×	-	X	X	+ -
Moore 2010	15	15	5	5	0.08	0.03	0.24	0.21		0.05 0).102	[-0.16; 0.27]	3.9%	×	+	X	X	8 -
Subgroup estimate	343	274							▲	0.07		[0.02; 0.13]	78.3%					
Heterogeneity: $I^2 = 60\%$, τ	= 0.060), p = (0.0080															
Test for effect in subgroup	: t ₉ = 3.1	10 (p =	= 0.012	6)														
Subacute Stroke																		
Eich 2004	25	25	0	0	0.31	0.16	0.17	0.13		0.15 0	0.043	[0.06; 0.24]	9.5%	-	+	+	+	🗴 😑
Hornby 2016	16	17	1	0	0.34	0.11	0.29	0.26		0.23 0).097	[0.04; 0.43]	4.2%	+	+	+	+	+ -
Kuys 2011	15	15	2	0	0.29	0.13	0.26	0.12		0.16 0	0.079	[0.00; 0.33]	5.5%	+	+	+	-	+ -
Pohl 2002	23	46	3	6	0.94	0.43	0.52	0.46	\longrightarrow	0.51 0).136	[0.24; 0.78]	2.5%	×	-	X	X	+ -
Subgroup estimate	79	103								0.21		[0.01; 0.41]	21.7%					
Heterogeneity: $I^2 = 55\%$, τ																		
Test for effect in subgroup	: t ₃ = 3.2	29 (p =	= 0.046	0)														
Overall estimate		377								0.10		[0.04; 0.16] 1	00.0%		👌 Hi			
Heterogeneity: $I^2 = 63\%$, τ															- So			
Residual heterogeneity: I ²	,			= 0.00	19				-0.2 0 0.2 0.4 0.6					9	+ Lo	ow ris	k of I	bias
Test for overall effect: t ₁₃ =			,						Fastest Gait Speed (m/s)									
Test for subgroup difference	ce: F(1,1	2) = 5	5.56 (p	= 0.036	62)													

Figure S4. Mean change (Δ **) differences for LT**_{mv} **versus control interventions: Daily walking activity.** Results from a random effects meta-analysis. Risk-of-bias assessment was performed using the RoB-2 tool, yielding an overall (O) judgment based on the following domains: R, Bias arising from the randomization process; D, Bias due to deviations from intended intervention; Mi, Bias due to missing outcome data; Me, Bias in measurement of the outcome; S, Bias in selection of the reported result. N, number of participants randomized; N_{imp}, number of randomized participants not included in the reported analysis whose outcomes were imputed; SD Δ , standard deviation of change; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.




Figure S5. Relative risk (RR) of a treatment-related serious adverse effect (SAE) for LT_{mv} versus control

interventions. Unable to perform meta-analysis because no treatment-related SAEs were reported in any study group. Only studies with some reporting about adverse events are shown. Risk-of-bias assessment was performed using the RoB-2 tool, yielding an overall (O) judgment based on the following domains: R, Bias arising from the randomization process; D, Bias due to deviations from intended intervention; Mi, Bias due to missing outcome data; Me, Bias in measurement of the outcome; S, Bias in selection of the reported result. LT_{mv}, moderate-to-vigorous intensity locomotor training; Total, number of participants exposed to at least some of the intervention.

		LT _{mv}	C	ontrol	Relative Risk of a Treatment-Related SA	E		Ris	sk o	f Bia	S	
Study	Events	Total	Events	Total	LTmv / Control	RR 95%-CI Weight	0	R	D	Mil	Me S	S
Ada 2003	0	14	0	15		0.0%	-	+	+	+	8	
Aguiar 2020	0	11	0	11		0.0%	-	+	+	+	8	+
Eich 2004	0	25	0	25		0.0%	-	+	+	+	8	
Gjellesvik 2021	0	36	0	34		0.0%	-	+	+	+	8	
Globas 2012	0	20	0	18		0.0%	-	+	+	+	8	
Gordon 2013	0	64	0	64		0.0%	-	-	+	+	×	
Holleran 2015	0	7	0	7		0.0%	-	-	+	+	X	
Hornby 2016	0	16	0	17		0.0%	-	+	+	+	X	
Hornby 2019	0	64	0	33		0.0%	-	+	+	+	X	
lvey 2015	0	24	0	27		0.0%	×	-	X	+	X	Ē
Klassen 2020	0	50	0	25		0.0%	•	+	+	+	X	Đ
Kuys 2011	0	15	0	15		0.0%	-	+	+	+	X	
Macko 2005	0	32	0	29		0.0%	×	-	X	+	X	
Pohl 2002	0	20	0	40		0.0%	×	-	X	×	8	Ð
Overall estimate	0	398	0	360		100.0%	ſ	🗙 Hi	gh ri	sk of b	oias	
Heterogeneity: $I^2 = NA^4$	%, τ = NA, <i>p</i>	= NA						-		conce	I	
Test for overall effect: 2					0.75 1 1.5			+ Lo	w ri	sk of b	ias	
				М	ore SAEs with Control More SAEs with LT Relative Risk	mv	L					

Figure S6. Relative risk (RR) of treatment-related pain for LT_{mv} versus control interventions. Results from a random effects meta-analysis. Only studies with some reporting about treatment-related pain are shown. Studies reporting no events in either group do not contribute any information about relative risk between groups. Risk-of-bias assessment was performed using the RoB-2 tool, yielding an overall (O) judgment based on the following domains: R, Bias arising from the randomization process; D, Bias due to deviations from intended intervention; Mi, Bias due to missing outcome data; Me, Bias in measurement of the outcome; S, Bias in selection of the reported result. LT_{mv} , moderate-to-vigorous intensity locomotor training; Total, number of participants exposed to at least some of the intervention; Weight, % contribution of each study to the overall pooled estimate; I^2 , % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.




Figure S7. Relative risk (RR) of a fall for LT_{mv} **versus control interventions.** Results from a random effects metaanalysis. Only studies with some reporting about falls are shown. Studies reporting no fallers in either group do not contribute any information about relative risk between groups. Risk-of-bias assessment was performed using the RoB-2 tool, yielding an overall (O) judgment based on the following domains: R, Bias arising from the randomization process; D, Bias due to deviations from intended intervention; Mi, Bias due to missing outcome data; Me, Bias in measurement of the outcome; S, Bias in selection of the reported result. LT_{mv}, moderate-to-vigorous intensity locomotor training; Total, number of participants with reported data; Weight, % contribution of each study to the overall pooled estimate; l^2 , % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.




Figure S8. Publication bias assessment. Points are individual study estimates and vertical dotted lines show the pooled estimate from the random effects model. Shaded areas show the significance region (p<0.05) for the null hypothesis of no LT_{mv} versus control difference. The expected manifestation of publication bias is an asymmetrical distribution of studies around the pooled estimate, with smaller studies (higher standard error; lower on y-axis) being more likely to be reported if they have statistically significant findings. This would result in smaller studies being disproportionately clustered in the significance region to the right of the pooled estimate, with missing (non-reported) small studies in the non-significance region and to the left of the pooled estimate. Bias estimates are weighted regression coefficients testing the linear association between standard error and effect size, where significant positive values (not present here) would suggest publication bias.




Figure S9. Variance of individual response (SD_{IR}²): **Comfortable gait speed.** Results from a random effects metaanalysis. SD_{IR} estimates and 95%CI can be obtained by taking the square root of the values in this figure. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (0.1-0.2 m/s), converted to SD_{IR}² units by halving and squaring (0.0025-0.01 [m/s]²). N, number of participants analyzed; SDA, standard deviation of change; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.




Figure S10. Variance of individual response (SD_{IR}²): **Fastest gait speed.** Results from a random effects metaanalysis. SD_{IR} estimates and 95%CI can be obtained by taking the square root of the values in this figure. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (0.1-0.2 m/s), converted to SD_{IR}² units by halving and squaring (0.0025-0.01 [m/s]²). N, number of participants analyzed; SD Δ , standard deviation of change; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.




Figure S11. Variance of individual response (SD_{IR}²): **Daily walking activity.** Results from a random effects metaanalysis. SD_{IR} estimates and 95%CI can be obtained by taking the square root of the values in this figure. N, number of participants analyzed; SD Δ , standard deviation of change; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.




Figure S12. Mean changes (Δ) within LT_{mv} groups: Comfortable gait speed. Results from a random (mixed) effects meta-analysis stratified by stroke chronicity. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (0.1-0.2 m/s). N, number of participants randomized; N_{imp}, number of randomized participants not included in the reported analysis whose outcomes were imputed; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study and subgroup to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.

Study	N LTmv	Nimp LTmv		Mean ∆ Within L1	Մ _{mv} Group	Es	stimate	SE	95%CI	Weight
Chronic Stroke										
Ada 2003	14	3			-		0.15	0.054	[0.03; 0.27]	7.1%
Ada 2013	68	0					0.14	0.021	[0.10; 0.19]	8.2%
Aguiar 2020	11	0					0.09	0.051	[-0.02; 0.20]	7.2%
Awad 2016	16	0					0.20	0.033	[0.13; 0.27]	7.9%
Globas 2012	20	2					0.06	0.020	[0.02; 0.11]	8.2%
Hornby 2019	64	0					0.17	0.020	[0.13; 0.20]	8.2%
lvey 2011	26	7					0.07	0.033	[-0.00; 0.14]	7.9%
lvey 2015	24	6		_ 			0.02	0.025	[-0.03; 0.07]	8.1%
Macko 2005	32	7					0.11	0.035	[0.03; 0.18]	7.8%
Moore 2010	15	5					0.05	0.059	[-0.08; 0.18]	6.9%
Subgroup estimate	290						0.11		[0.06; 0.15]	77.7%
Heterogeneity: $I^2 = 77\%$,	$\tau = 0.073$, <i>p</i> < 0.0001								
Test for effect in subgroup	p: t ₉ = 5.7	7 (<i>p</i> = 0.0003)								
Subacute Stroke										
Hornby 2016	16	1					0.26	0.056	[0.14; 0.38]	7.0%
Klassen 2020	50	1				—	0.50	0.019	[0.46; 0.54]	8.3%
Kuys 2011	15	2					0.25	0.057	[0.13; 0.38]	7.0%
Subgroup estimate	81						0.36		[-0.00; 0.73]	22.3%
Heterogeneity: $I^2 = 93\%$,	$\tau = 0.073$, <i>p</i> < 0.0001								
Test for effect in subgroup	p: <i>t</i> ₂ = 4.2	5 (<i>p</i> = 0.0512)								
Overall estimate	371						0.16		[0.08; 0.24]	100.0%
Heterogeneity: $I^2 = 97\%$,	τ = 0.126	, <i>p</i> < 0.0001			I					
Residual heterogeneity: /			-0.2	0 0.2	0.4	0.6				
Test for overall effect: t_{12}				Comfortable Gait S	Speed (m/s)					
Test for subgroup differen	nce: F(1,1	1) = 21.74 (p = 0.0007	7)							

Figure S13. Mean changes (Δ **) within LT**_{mv} **groups: Fastest gait speed.** Results from a random (mixed) effects metaanalysis stratified by stroke chronicity. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (0.1-0.2 m/s). N, number of participants randomized; N_{imp}, number of randomized participants not included in the reported analysis whose outcomes were imputed; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study and subgroup to the overall pooled estimate; I^2 , % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.

Study	N LTmv	Nimp LTmv		Mean Δ	Within I	LT _{mv} G	roup		Estimate	SE	95%CI	Weight
Chronic Stroke												
Ada 2013	68	0		-					0.17	0.028	[0.12; 0.23]	7.6%
Aguiar 2020	11	0		-					-0.05	0.066	[-0.20; 0.10]	7.0%
Awad 2016	16	0		-	_				0.19	0.060	[0.06; 0.32]	7.1%
Gjellesvik 2021	36	0							0.09	0.059	[-0.03; 0.21]	7.1%
Globas 2012	20	2							0.11	0.029	[0.04; 0.17]	7.6%
Hornby 2019	64	0		-	F				0.27	0.027	[0.21; 0.32]	7.6%
lvey 2015	24	8		-					0.06	0.022	[0.01; 0.11]	7.7%
Luft 2008	57	20							0.08	0.031	[0.02; 0.15]	7.6%
Macko 2005	32	7							0.13	0.051	[0.02; 0.23]	7.3%
Moore 2010	15	5							0.08	0.077	[-0.09; 0.26]	6.7%
Subgroup estimate	343								0.12		[0.06; 0.18]	73.1%
Heterogeneity: $I^2 = 82\%$, τ = 0.122,	<i>p</i> < 0.0001										
Test for effect in subgrou	up: $t_9 = 4.35$	5 (<i>p</i> = 0.0018)										
Subacute Stroke												
Eich 2004	25	0			+				0.31	0.034	[0.24; 0.38]	7.5%
Hornby 2016	16	1		+	•				0.34	0.075	[0.18; 0.50]	6.8%
Kuys 2011	15	2			•				0.29	0.072	[0.14; 0.45]	6.8%
Pohl 2002	23	3						Ⅰ →	0.94	0.115	[0.70; 1.19]	5.8%
Subgroup estimate	79								0.43		[-0.02; 0.87]	26.9%
Heterogeneity: $I^2 = 89\%$	$, \tau = 0.122,$	<i>p</i> < 0.0001										
Test for effect in subgrou	up: $t_3 = 3.07$	7 (<i>p</i> = 0.0546)										
Overall estimate	422								0.20		[0.08; 0.33]	100.0%
Heterogeneity: $I^2 = 90\%$												
Residual heterogeneity:)1 -0.2	0 0.2	0.4	0.6	0.8	1				
Test for overall effect: t_{13} Test for subgroup differe)57)	Fastes	t Gait S _l	peed (I	n/s)					


Figure S14. Mean changes (Δ) within LT_{mv} groups: 6-minute walk test. Results from a random (mixed) effects metaanalysis stratified by stroke chronicity. The gray shaded region in the forest plot shows a range of clinically important difference thresholds in the literature (14-50 m). N, number of participants randomized; N_{imp}, number of randomized participants not included in the reported analysis whose outcomes were imputed; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study and subgroup to the overall pooled estimate; I², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.

	Ν	Nimp					
Study	LTmv	LTmv	Mean Δ Within LT _{mv} Group Es	timate	SE	95%CI	Weight
Chronic Stroke							
Ada 2003	14	3		81	21.9	[32; 129]	4.8%
Ada 2013	68	0		46	6.3	[33; 58]	6.2%
Aguiar 2020	11	0		48	17.5	[9; 87]	5.3%
Awad 2016	16	0		87	17.2	[50; 124]	5.3%
Gjellesvik 2021	36	0		41	10.2	[21; 62]	6.0%
Globas 2012	20	2		52	10.8	[30; 75]	5.9%
Gordon 2013	64	0		43	8.0	[27; 59]	6.1%
Holleran 2015	7	1		57	22.7	[-2; 115]	4.7%
Hornby 2019	64	0		90	8.3	[73; 106]	6.1%
lvey 2011	26	7		30	10.4	[9; 52]	6.0%
lvey 2015	24	6		50	12.8	[23;77]	5.8%
Luft 2008	57	20		21	7.5	[6; 37]	6.2%
Macko 2005	32	7		40	12.5	[14; 65]	5.8%
Moore 2010	15	5		21	23.5	[-32; 74]	4.7%
Subgroup estimate	454			50		[37; 62]	78.9%
Heterogeneity: $I^2 = 75\%$	ώ, τ = 23.8,	<i>p</i> < 0.0001					
Test for effect in subgro	pup: $t_{13} = 8$.	64 (<i>p</i> < 0.0001)					
Subacute Stroke							
Eich 2004	25	0		91	8.7	[73; 109]	6.1%
Hornby 2016	16	1		113	28.8	[52; 175]	4.1%
Klassen 2020	50	1		176	6.7	[162; 189]	6.2%
Kuys 2011	15	2		113		[63; 162]	4.7%
Subgroup estimate	106			127		[61; 193]	21.1%
Heterogeneity: $I^2 = 95\%$	ώ, τ = 23.8,	<i>p</i> < 0.0001					
Test for effect in subgro							
Overall estimate	560			66		[46; 86]	100.0%
Heterogeneity: $I^2 = 96\%$	%, τ = 38.3,	<i>p</i> < 0.0001					
Residual heterogeneity	: <i>I</i> ² = 87%,	$\tau = 23.8, p < 0.00$	1 -50 0 50 100 150				
Test for overall effect: t	17 = 6.96 (p	0 < 0.0001)	6-Minute Walk Test (m)				
Test for subgroup differ	rence: F(1,1	6) = 25.65 (p = 0					

Figure S15. Mean changes (Δ **) within LT**_{mv} **groups: Daily walking activity.** Results from a random effects metaanalysis. N, number of participants randomized; N_{imp}, number of randomized participants not included in the reported analysis whose outcomes were imputed; LT_{mv}, moderate-to-vigorous intensity locomotor training; SE, standard error; Weight, % contribution of each study to the overall pooled estimate; l², % of variance attributed to between-study heterogeneity; τ , estimated between-study standard deviation; Heterogeneity p-values are from Cochran's Q test.

Study		Nimp LTmv	Mean Δ Within LT _{mv} Group	Estimate	SE	95%CI	Weight
Gjellesvik 2021	36	5	÷	-1507	645	[-2824; -190]	22.1%
Hornby 2016	16	1		955	539	[-202; 2112]	24.5%
Hornby 2019	64	26		469	212	[39; 898]	31.0%
lvey 2015	24	6		1002	636	[-340; 2345]	22.3%
Overall estimate	140			270		[-1518; 2057]	100.0%
Heterogeneity: $I^2 = 72\%$	%, τ = 937, /	v = 0.0129					
Test for overall effect: $t_3 = 0.48$ ($p = 0.6640$)			-2000 -1000 0 1000 2000 Daily Walking Activity (steps/day)				

Figure S16. Estimated proportions of participants with meaningful gains during LT_{mv}. Graphs show the estimated distributions of individual changes (Δ) during LT_{mv}, based on the meta-analysis results. Separate distributions were calculated for each outcome measure (from left to right: comfortable gait speed, fastest gait speed, 6-minute walk test) and for each stroke chronicity subgroup (top panel, chronic; bottom panel, subacute). The mean of each distribution is the meta-analysis estimate of the mean Δ within LT_{mv} groups, and the SD of each distribution is the meta-analysis estimate of the true individual variability in responsiveness). Reported probabilities (P) are the % of individual Δ scores that were at or above different clinically important difference thresholds from the literature. These thresholds ranged from 0.10 m/s (small) to 0.20 m/s (large) for gait speed²⁸⁻³¹ and from 14 m (small) to 50 m (large) for the 6-minute walk test.



APPENDIX

Example Search Strategy (PubMed)

- 1. Stroke [MeSH Terms] OR cerebrovascular accident OR cva OR hemipleg* OR hemipar* OR brain infarction OR brain stem infarction OR cerebral infarction OR subcortical infarction OR cerebral hemorrhage OR brain hemorrhage OR brain stem hemorrhage OR subcortical hemorrhage OR interventricular hemorrhage OR subarachnoid hemorrhage OR intracerebral hemorrhage
- 2. Walk* OR gait OR ambulat* OR locomot* OR treadmill OR overground OR step*
- 3. Exercis* OR train* OR program OR rehabilitat* OR intervention
- 4. NOT (animals[MeSH Terms] NOT humans[MeSH Terms])
- 5. NOT "meta-analysis"[Publication Type] NOT "systematic review"[Publication Type] NOT "review"[Publication Type]
- 6. "randomized controlled trial"[Publication Type] AND "clinical trial"[Publication Type])
- 7. 1995/01/01:2022/03/01[Date Publication]
- #1 AND #2 AND #3 AND #4 AND #5 AND #6 AND #7

REFERENCES

1. Hornby TG, Reisman DS, Ward IG, et al. Clinical practice guideline to improve locomotor function following chronic stroke, incomplete spinal cord injury, and brain injury. *J Neurol Phys Ther*. 2020;44(1):49-100. doi: 10.1097/NPT.000000000000303 [doi].

2. Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. *Cochrane handbook for systematic reviews of interventions version* 6.3. Cochrane; 2022:<u>www.training.cochrane.org/handbook.</u>

3. Mills HL, Higgins JPT, Morris RW, et al. Detecting heterogeneity of intervention effects using analysis and meta-analysis of differences in variance between trial arms. *Epidemiology*. 2021;32(6):846-854.

4. Swinton PA, Hemingway BS, Saunders B, Gualano B, Dolan E. A statistical framework to interpret individual response to intervention: Paving the way for personalized nutrition and exercise prescription. *Frontiers in nutrition (Lausanne)*. 2018;5:41.

5. Danks KA, Pohlig R, Reisman DS. Combining fast-walking training and a step activity monitoring program to improve daily walking activity after stroke: A preliminary study. *Arch Phys Med Rehabil*. 2016;97(9 Suppl):185.

6. Holleran CL, Straube DD, Kinnaird CR, Leddy AL, Hornby TG. Feasibility and potential efficacy of highintensity stepping training in variable contexts in subacute and chronic stroke. *Neurorehabil Neural Repair*. 2014;28(7):643-651.

7. Hornby TG, Henderson CE, Plawecki A, et al. Contributions of stepping intensity and variability to mobility in individuals poststroke. *Stroke*. 2019;50(9):2492-2499. doi: 10.1161/STROKEAHA.119.026254 [doi].

8. Macko RF, Ivey FM, Forrester LW, et al. Treadmill exercise rehabilitation improves ambulatory function and cardiovascular fitness in patients with chronic stroke: A randomized, controlled trial. *Stroke*. 2005;36(10):2206-2211.

9. Dean CM, Ada L, Lindley RI. Treadmill training provides greater benefit to the subgroup of communitydwelling people after stroke who walk faster than 0.4m/s: A randomised trial. *J Physiother*. 2014;60(2):97-101.

10. Kim DK, Oh DW. Repeated use of 6-min walk test with immediate knowledge of results for walking capacity in chronic stroke: Clinical trial of fast versus slow walkers. *J Stroke Cerebrovasc Dis.* 2019;28(11):104337. doi: S1052-3057(19)30390-8 [pii].

11. Lam JM, Globas C, Cerny J, et al. Predictors of response to treadmill exercise in stroke survivors. *Neurorehabil Neural Repair*. 2010;24(6):567-574.

12. Luft AR, Macko RF, Forrester LW, et al. Treadmill exercise activates subcortical neural networks and improves walking after stroke. A randomized controlled trial. *Stroke*. 2008;39(12):3341-50.

13. Atkinson G, Batterham AM. True and false interindividual differences in the physiological response to an intervention. *Exp Physiol.* 2015;100(6):577-588.

14. Hopkins G. Individual responses made easy. *Journal of applied physiology (1985)*. 2015;118(12):1444-1446.

15. Watson JA, Ryan CG, Atkinson G, et al. Inter-individual differences in the responses to pain neuroscience education in adults with chronic musculoskeletal pain: A systematic review and meta-analysis of randomized controlled trials. *The journal of pain*. 2020;22(1):9-20.

16. Williamson PJ, Atkinson G, Batterham AM. Inter-individual differences in weight change following exercise interventions: A systematic review and meta-analysis of randomized controlled trials. *Obesity reviews*. 2018;19(7):960-975.

17. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI, Health Outcomes, Policy, and Economics (HOPE) Collaborative Group. Understanding heterogeneity in meta-analysis: The role of meta-regression. *Int J Clin Pract*. 2009;63(10):1426-1434.

18. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? *Stat Med*. 2002;21(11):1559-1573.

19. American College of Sports Medicine, (ACSM). *ACSM's guidelines for exercise testing and prescription.* 9th ed. Philadephia, PA: Lippincott Williams & Wilkins; 2014.

20. Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: A joint position statement of the european association for cardiovascular prevention and rehabilitation, the american association of cardiovascular and pulmonary rehabilitation, and the canadian association of cardiac rehabilitation. *J Cardiopulm Rehabil Prev.* 2012;32(6):327-350.

21. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898. doi: 10.1136/bmj.l4898 [doi].

22. Boyne P, Welge J, Kissela B, Dunning K. Factors influencing the efficacy of aerobic exercise for improving fitness and walking capacity after stroke: A meta-analysis with meta-regression. *Arch Phys Med Rehabil*. 2017;98(3):581-595. doi: S0003-9993(16)31143-1 [pii].

23. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. *NIH Publication No 09-5410*. 2009.

24. R Development Core Team. R: A language and environment for statistical computing. *R Foundation for Statistical Computing, Vienna, Austria.* 2004.

25. Schwarzer G. Meta: General package for meta-analysis. R package version 5.2-0. <u>https://github.com/guido-s/meta/.</u> Updated 2022.

26. Marzolini S, Wu CY, Hussein R, et al. Associations between time after stroke and exercise training outcomes: A meta-regression analysis. *J Am Heart Assoc*. 2021;10(24):e022588. doi: 10.1161/JAHA.121.022588 [doi].

27. Ebrahim S, Akl EA, Mustafa RA, et al. Addressing continuous data for participants excluded from trial analysis: A guide for systematic reviewers. *J Clin Epidemiol*. 2013;66(9):1014-1021.e1. doi: 10.1016/j.jclinepi.2013.03.014 [doi].

28. Bohannon RW, Glenney SS. Minimal clinically important difference for change in comfortable gait speed of adults with pathology: A systematic review. *J Eval Clin Pract.* 2014;20(4):295-300.

29. Fulk GD, Ludwig M, Dunning K, Golden S, Boyne P, West T. Estimating clinically important change in gait speed in people with stroke undergoing outpatient rehabilitation. *J Neurol Phys Ther.* 2011;35(2):82-89.

30. Tilson JK, Sullivan KJ, Cen SY, et al. Meaningful gait speed improvement during the first 60 days poststroke: Minimal clinically important difference. *Phys Ther.* 2010;90(2):196-208.

31. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc*. 2006;54(5):743-749.

32. Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: A systematic review. *J Eval Clin Pract*. 2017;23(2):377-381.

33. Fulk GD, He Y. Minimal clinically important difference of the 6-minute walk test in people with stroke. *Journal of neurologic physical therapy*. 2018;42(4):235-240.

34. Ada L, Dean CM, Hall JM, Bampton J, Crompton S. A treadmill and overground walking program improves walking in persons residing in the community after stroke: A placebo-controlled, randomized trial. *Arch Phys Med Rehabil.* 2003;84(10):1486-1491.

35. Ada L, Dean CM, Lindley R. Randomized trial of treadmill training to improve walking in communitydwelling people after stroke: The AMBULATE trial. *Int J Stroke*. 2013;8(6):436-444.

36. Aguiar LT, Nadeau S, Britto RR, et al. Effects of aerobic training on physical activity in people with stroke: A randomized controlled trial. *NeuroRehabilitation*. 2020;46(3):391-401. doi: 10.3233/NRE-193013 [doi].

37. Awad LN, Reisman DS, Pohlig RT, Binder-Macleod SA. Reducing the cost of transport and increasing walking distance after stroke: A randomized controlled trial on fast locomotor training combined with functional electrical stimulation. *Neurorehabil Neural Repair*. 2016;30(7):661-670.

38. Eich HJ, Mach H, Werner C, Hesse S. Aerobic treadmill plus bobath walking training improves walking in subacute stroke: A randomized controlled trial. *Clin Rehabil*. 2004;18(6):640-651.

39. Gjellesvik TI, Becker F, Tjønna AE, et al. Effects of high-intensity interval training after stroke (the HIIT stroke study) on physical and cognitive function: A multicenter randomized controlled trial. *Arch Phys Med Rehabil*. 2021;102(9):1683-1691.

40. Globas C, Becker C, Cerny J, et al. Chronic stroke survivors benefit from high-intensity aerobic treadmill exercise: A randomized control trial. *Neurorehabil Neural Repair*. 2012;26(1):85-95.

41. Gordon CD, Wilks R, McCaw-Binns A. Effect of aerobic exercise (walking) training on functional status and health-related quality of life in chronic stroke survivors: A randomized controlled trial. *Stroke*. 2013;44(4):1179-1181.

42. Holleran CL, Rodriguez KS, Echauz A, Leech KA, Hornby TG. Potential contributions of training intensity on locomotor performance in individuals with chronic stroke. *J Neurol Phys Ther.* 2015;39(2):95-102.

43. Hornby TG, Holleran CL, Hennessy PW, et al. Variable intensive early walking poststroke (VIEWS): A randomized controlled trial. *Neurorehabil Neural Repair*. 2016;30(5):440-50.

44. Ivey FM, Ryan AS, Hafer-Macko CE, Macko RF. Improved cerebral vasomotor reactivity after exercise training in hemiparetic stroke survivors. *Stroke*. 2011;42(7):1994-2000.

45. Ivey FM, Stookey AD, Hafer-Macko CE, Ryan AS, Macko RF. Higher treadmill training intensity to address functional aerobic impairment after stroke. *J Stroke Cerebrovasc Dis*. 2015;24(11):2539-2546.

46. Klassen TD, Dukelow SP, Bayley MT, et al. Higher doses improve walking recovery during stroke inpatient rehabilitation. *Stroke (1970)*. 2020;51(9):2639-2648.

47. Kuys SS, Brauer SG, Ada L. Higher-intensity treadmill walking during rehabilitation after stroke in feasible and not detrimental to walking pattern or quality: A pilot randomized trial. *Clin Rehabil*. 2011;25(4):316-326.

48. Moore JL, Roth EJ, Killian C, Hornby TG. Locomotor training improves daily stepping activity and gait efficiency in individuals poststroke who have reached a "plateau" in recovery. *Stroke*. 2010;41(1):129-135.

49. Pohl M, Mehrholz J, Ritschel C, Ruckriem S. Speed-dependent treadmill training in ambulatory hemiparetic stroke patients: A randomized controlled trial. *Stroke*. 2002;33(2):553-558.

50. Gjellesvik TI, Becker F, Tjonna AE, et al. Effects of high-intensity interval training after stroke (the HIIT-stroke study): A multicenter randomized controlled trial. *Arch Phys Med Rehabil*. 2020;101(6):939-947. doi: S0003-9993(20)30141-6 [pii].

51. Hornby TG, Plawecki A, Lotter JK, Scofield ME, Lucas E, Henderson CE. Gains in daily stepping activity in people with chronic stroke after high-intensity gait training in variable contexts. *Phys Ther*. 2022;102(8):10.1093/ptj/pzac073. doi: pzac073 [pii].

52. Lang CE, Holleran CL, Strube MJ, et al. Improvement in the capacity for activity versus improvement in performance of activity in daily life during outpatient rehabilitation. *J Neurol Phys Ther*. 2022. doi: 10.1097/NPT.000000000000413 [doi].

53. Ardestani MM, Henderson CE, Hornby TG. Improved walking function in laboratory does not guarantee increased community walking in stroke survivors: Potential role of gait biomechanics. *J Biomech*. 2019;91:151-159. doi: S0021-9290(19)30343-4 [pii].

54. Miller A, Pohlig RT, Wright T, Kim HE, Reisman DS. Beyond physical capacity: Factors associated with real-world walking activity after stroke. *Arch Phys Med Rehabil*. 2021;102(10):1880-1887.e1. doi: S0003-9993(21)00304-X [pii].

55. Miller AE, Russell E, Reisman DS, Kim HE, Dinh V. A machine learning approach to identifying important features for achieving step thresholds in individuals with chronic stroke. *PLoS One*. 2022;17(6):e0270105. doi: 10.1371/journal.pone.0270105 [doi].

56. Thilarajah S, Mentiplay BF, Bower KJ, et al. Factors associated with post-stroke physical activity: A systematic review and meta-analysis. *Arch Phys Med Rehabil*. 2018;99(9):1876-1889. doi: S0003-9993(17)31264-9 [pii].

57. Miller A, Pohlig RT, Reisman DS. Relationships among environmental variables, physical capacity, balance self-efficacy, and real-world walking activity post-stroke. *Neurorehabil Neural Repair*. 2022;36(8):535-544. doi: 10.1177/15459683221115409 [doi].

58. Boyne P, Doren S, Scholl V, et al. Preliminary outcomes of combined treadmill and overground highintensity interval training in ambulatory chronic stroke. *Frontiers in Neurology*. 2022;13:812875. <u>https://www.frontiersin.org/article/10.3389/fneur.2022.812875</u>.

59. Boyne P, Billinger SA, Reisman DS, et al. A multicenter randomized comparison of high-intensity interval training and moderate-intensity exercise to recover walking post-stroke: Results of the HIT-stroke trial. *medRxiv* 22278246 [*Preprint*]. 2022:https://doi.org/10.1101/2022.08.01.22278246.